NASDAQ:NBTX Nanobiotix (NBTX) Stock Price, News & Analysis $3.63 +0.07 (+1.94%) Closing price 03/28/2025 12:30 PM EasternExtended Trading$3.63 +0.00 (+0.03%) As of 03/28/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nanobiotix Stock (NASDAQ:NBTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nanobiotix alerts:Sign Up Key Stats Today's Range$3.56▼$3.6150-Day Range$3.03▼$4.1652-Week Range$2.76▼$7.51Volume1,137 shsAverage Volume21,594 shsMarket Capitalization$171.05 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company OverviewNanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Read More… Remove Ads Nanobiotix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreNBTX MarketRank™: Nanobiotix scored higher than 52% of companies evaluated by MarketBeat, and ranked 533rd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingNanobiotix has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNanobiotix has only been the subject of 1 research reports in the past 90 days.Read more about Nanobiotix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nanobiotix are expected to grow in the coming year, from ($1.18) to ($0.86) per share.Read more about Nanobiotix's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of Nanobiotix has been sold short.Short Interest Ratio / Days to CoverNanobiotix has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nanobiotix has recently decreased by 68.60%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNanobiotix does not currently pay a dividend.Dividend GrowthNanobiotix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.02% of the float of Nanobiotix has been sold short.Short Interest Ratio / Days to CoverNanobiotix has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nanobiotix has recently decreased by 68.60%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.94 News SentimentNanobiotix has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Nanobiotix this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nanobiotix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.45% of the stock of Nanobiotix is held by insiders.Percentage Held by InstitutionsOnly 38.81% of the stock of Nanobiotix is held by institutions.Read more about Nanobiotix's insider trading history. Receive NBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter. Email Address NBTX Stock News HeadlinesNanobiotix reports promising NSCLC treatment study resultsMarch 29 at 2:43 PM | investing.comNanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLCMarch 27, 2025 | globenewswire.comNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.March 31, 2025 | Brownstone Research (Ad)Nanobiotix FY2024 EPS Estimate Lifted by Leerink PartnrsMarch 22, 2025 | americanbankingnews.comNANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer ConferenceMarch 20, 2025 | globenewswire.comNanobiotix amends global licensing agreement with Janssen PharmaceuticaMarch 18, 2025 | markets.businessinsider.comNANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026March 17, 2025 | globenewswire.comNanobiotix files $200M mixed securities shelfMarch 7, 2025 | markets.businessinsider.comSee More Headlines NBTX Stock Analysis - Frequently Asked Questions How have NBTX shares performed this year? Nanobiotix's stock was trading at $2.87 on January 1st, 2025. Since then, NBTX shares have increased by 26.4% and is now trading at $3.6290. View the best growth stocks for 2025 here. When did Nanobiotix IPO? Nanobiotix (NBTX) raised $95 million in an initial public offering on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont acted as the underwriters for the IPO. Who are Nanobiotix's major shareholders? Nanobiotix's top institutional shareholders include OLD Mission Capital LLC (0.10%), Jane Street Group LLC (0.05%), Millennium Management LLC (0.03%) and Geode Capital Management LLC (0.02%). How do I buy shares of Nanobiotix? Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nanobiotix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nanobiotix investors own include PayPal (PYPL), Sirius XM (SIRI), Ardelyx (ARDX), BridgeBio Pharma (BBIO), Cogent Communications (CCOI), Citius Pharmaceuticals (CTXR) and Datadog (DDOG). Company Calendar Today3/30/2025Next Earnings (Estimated)3/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NBTX CIK1760854 Webwww.nanobiotix.com Phone33-1-40-26-04-70FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+230.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.42 Quick RatioN/A Sales & Book Value Annual Sales$36.22 million Price / Sales4.72 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-90.73Miscellaneous Outstanding Shares47,133,000Free Float45,507,000Market Cap$171.05 million OptionableNot Optionable Beta0.28 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NBTX) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.